Uncategorized – Wounds

Case 4: SNAP™ Therapy Diabetic Foot Wound

Patient information:
68-year old male

Wound history:
Trauma to dorsal foot from door.

Dimensons:
Prior to SNAP™ Therapy, the wound measured 70mm x 54mm with a depth of 4mm without undermining.

Comorbidities:
Diabetes Mellitus, Smoker, Peripheral Vascular Disease, Coronary Artery Disease, COPD, Hypertension, Hyperlipidemia.

SNAP™ therapy treatment:
The patient was treated with SNAP™ Therapy for 3 weeks until full granulation of the wound bed was achieved. Then SNAP™ Therapy was used in conjunction with a cellular tissue product for an additional 5 weeks.

Outcome:
Wound closure was achieved at 9 weeks post-initiation of SNAP™ Therapy.

Case 3: V.A.C. VERAFLO CLEANSE CHOICE™ Dressing − Diabetic Foot
Author: Douglas Duke, DO Director of Wound Care Flowers Hospital, Dothan, AL

INTRODUCTION
A 54-year-old male was admitted to the hospital with chronic left foot wound of unknown duration (Figure A). Patient comorbidities included hypertension, diabetes mellitus, and Charcot foot.

Baseline:
The patient was treated with an intravenous antibiotic regimen and underwent surgical debridement with excision of necrotic tissue (Figure B). Following debridement, the wound was managed with V.A.C. VERAFLO™ Therapy using V.A.C. VERAFLO CLEANSE CHOICE™ Dressing. The contact layer of the V.A.C. VERAFLO CLEANSE CHOICE™ Dressing was placed on the devitalized wound bed, followed by the cover layer. Fifty milliliters of a commercially available hypochlorous solution (Vashe® Wound Therapy Solution, SteadMed Medical, Fort Worth, TX) was instilled with a dwell time of 10
minutes, followed by 3.5 hours of continuous negative pressure at -125mmHg. After 2 days of V.A.C. VERAFLO™ Therapy, the V.A.C. VERAFLO CLEANSE CHOICE™ Dressing was changed (Figure C), and the wound bed displayed healthy granulation tissue with minimal devitalized tissue or thick slough. After 14 days and 4 dressing changes, therapy was discontinued. A human dermal collagen matrix (GRAFTJACKET™, Wright Medical Group, Memphis, TN) was then applied to the wound for closure (Figure D).

Patient data and photos courtesy of Douglas Duke, DO; Director of Wound Care, Flowers Hospital, Dothan, AL

As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient’s circumstances and condition.

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.

Copyright 2017, 2018 KCI Licensing, Inc. All rights reserved. Graftjacket is a trademark of Wright Medical Group. Unless otherwise designated, all trademarks are proprietary to KCI Licensing, Inc., its affiliates and/or licensors. PRA-PM-EU-00075 (08/18)

Figure C: Wound after first V.A.C VERAFLO CLEANSE CHOICETM

Figure D; Application of human dermal-collagen matrix